Clinical Trial Update: Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating a bladder-sparing regimen of tislelizumab plus gemcitabine and cisplatin for PD-L1 positive muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: RenJi Hospital | Conditions: Urothelial Carcinoma Bladder, PD-1 Inhibitor | Phase 2 | Status: UNKNOWN